International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-5 doi: 10.5281/zenodo.8401397
Original Article
Phenotypic and Genotypic Detection of Extended Spectrum Beta Lactamase Enzyme in Klebsiella Pneumoniae Isolates from the Clinical Specimens of the Patients in a Tertiary Care Hospital
 ,
 ,
 ,
Published
Oct. 2, 2023
Abstract

Background: Klebsiella pneumoniae can cause a number of diseases, such as pneumonia, bloodstream infections, meningitis, and urinary tract infections. Depending on the infection site, the symptoms of Klebsiell apneumoniae infection vary. The purpose of this study is to determine the prevalence of the ESBL enzymes in Klebsiella pneumoniae isolates using phenotypic techniques from various hospital wards and the identification of ESBL resistance genes such as CTX, TEM and SHV.

Method: Different clinical samples from a tertiary care hospital were used to obtain Klebsiella pneumoniae isolates, which were then identified using a conventional disc diffusion technique and Combined double disc method, ESBLs were screened. The CTX, TEM, and SHV genes were genotypically detected using Multiplex PCR in accordance with the recommended procedure.

Result: The pattern of Antimicrobial susceptibility testing revealed that the most resistant antibiotics include, CAZ (76.67%), CTX(74.07%), CXM(72.67%), followed by TOB(72%), and PIT (67%). Out of 150 Klebsiella pneumoniae isolates, ESBL Combined double disc method positive are ceftazidime+clavulinicacid115 (74.7%) and, cefotaxime+clavulinic acid positive, 112 (74.7%). By using the Multiplex PCR technique, the CTX and SHV and TEM genes were 65.3% 51.3% and41.3% recorded respectively.

Conclusion: Most Klebsiella pneumoniae isolates that produced ESBLs have the CTX gene.

Recommended Articles
Loading Image...
Volume-4, Issue-5
Citations
2272 Views
242 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved